Vanda PharmaceuticalsVNDA
Recorded

Vanda Pharmaceuticals Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

JamesAnalyst

Yep. Great. Well, happy to be here with the next session with Vanda Pharmaceuticals. We have Kevin Moran, CFO. A lot going on for you guys, so maybe we can just take your time, do an intro, an overview of kind of everything going on, and then we can jump into some Q&A.

Kevin MoranCFO

Yeah, perfect. Well, first of all, thanks to James and to the entire Stifel team for having us. Very excited to be here today and to meet with folks. For just a bit of a table set with Vanda, for those who aren't familiar with it, we're a pharmaceutical company based in Washington, D.C., with more than 500 employees. We have five products approved, hopefully a sixth coming in the next month, across a wide range of therapeutic areas, and we have a very robust pipeline with a number of assets, including those that are approved and hopefully soon to be approved in development for other indications, and then a host of other assets beyond just those in development as well.

Kevin MoranCFO

With the five products that we have on the market, we have two atypical antipsychotics, Fanapt, which is approved for schizophrenia and bipolar disorder, as well as BYSANTI, which is also approved for schizophrenia and bipolar disorder. We have HETLIOZ, which is a circadian regulator approved for two orphan sleep indications here in the U.S., non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome. That product is also approved in Europe for non-24-hour sleep-wake disorder as well, but not for nighttime sleep disturbances in Smith-Magenis syndrome. We have PONVORY, which is approved for multiple sclerosis, and was acquired from J&J a few years ago. In addition to that, we have the recently approved NEREUS, which is approved for motion sickness and was approved towards the end of last year, and that's the five assets that are approved.

Kevin MoranCFO

The sixth asset, which could be approved in December, where we have a PDUFA date, is imsidolimab, or Quimilza, which we in-licensed from Anaptys last year, and is under review by the FDA for generalized pustular psoriasis, GPP. We ended the third quarter with about $140 million in cash, and that's coming off the heels of ending last year with about $260 million in cash. Obviously, that's about a $120 million burn through the first three quarters of the year. What we've communicated about that is that over the course of the most recent quarters, we've been making significant investments in our late-stage clinical assets, where we've had four phase III readouts, most recently with our positive phase III results for NEREUS and GLP-1.

Kevin MoranCFO

We've been manufacturing commercial launch supplies for the two recently approved products, NEREUS and BYSANTI, as well as the hopefully third approved product, imsidolimab, as well as the commercial infrastructure that goes into those product launches. With that, we expected, coming off the second quarter, that we'd begin to see expenses moderate as soon as the fourth quarter and as we headed into next year, and we communicated that we expected our cash to be sufficient through at least 2027, if not longer. In a positive development, obviously, we saw the third quarter operating expense come in significantly below what we'd seen in the second quarter, a bit ahead of schedule in terms of the expense moderation as we head into the end of the year. From the kind of recent milestones and upcoming highlights, we had two products approved in the last 12 months.

Kevin MoranCFO

We're hoping it's going to be three within a 12-month period, which is semi-unheard of, having a company of our size having three products approved in such a short period of time. We've had readout on three phase III trials in the late part of this year, including, as I mentioned, the GLP-1 phase III results. For BYSANTI, in addition to that product launching by the end of the year, we've got upcoming phase III results for BYSANTI in MDD, which obviously represents a very significant market opportunity in the atypical antipsychotic class, and so we're incredibly excited to hopefully read out on positive results there next year and move forward with potentially an sNDA for BYSANTI.

Kevin MoranCFO

Lots going on, lots of exciting things that have happened in the last 12 months with the FDA decisions that we've already seen and the clinical readouts that we've reported, and lots more to come in the coming quarters with another PDUFA date, another clinical trial readout next year, and the upcoming launch of BYSANTI.

JamesAnalyst

Yep. Great. So yeah, maybe we can just start with kind of Fanapt, BYSANTI, and just kind of that sort of dynamics. I guess, as it relates to Fanapt and sort of what you've seen, what has been sort of the drivers of sort of within this atypical antipsychotic kind of category, and what's sort of the outlook at maybe more like a class level, and how you guys are going to position this sort of franchise?

Kevin MoranCFO

Yeah. For a bit of background on Fanapt has been in the market for quite some time. Approved back in 2009, originally for schizophrenia. It was licensed to Novartis. Novartis originally commercialized it. We reacquired the rights in the 2014 timeframe and relaunched it under the Vanda bannerhead. As we clarified kind of the exclusivity period, we then launched a phase III program for bipolar disorder, which ultimately was successful and led to an FDA approval for that indication in 2024. When we got that positive response from the FDA and launched the commercial expansion around bipolar, Fanapt had been essentially flat from a revenue perspective for several years, and underneath that was that the units had been declining by a very small amount, 3%-5%, let's say, a year, and any kind of price favorability had offset that to kind of keep the revenue stabilized.

Kevin MoranCFO

Since we launched in bipolar disorder, we have seen a very significant growth in prescription volume, over 30% last year, and on track for a similar performance this year. That is what has been driving the revenue growth, both not just beyond the existing volume that it was in 2024, but likely what was a declining volume. The area kind of above that declining curve, I would say, is all attributable to the bipolar indication. As part of that, we have significantly expanded our sales footprint from prior to that approval in the neighborhood of about 50 representatives, and first we went up to about 150, and then at about this time last year, we went up to 300, which is, I would say, competitive within the class, although still on the smaller side relative to some of the other competitors in the space.

Kevin MoranCFO

Most of that growth that we are seeing is likely attributable to bipolar disorder and the significant expansion of targets that we began calling on with that indication expansion. The class itself, there is a highly genericized portion of the class, and then there is the branded portion of the class. The branded portion of the class is a several multi-billion dollar revenue opportunity, just to give you some sense of the scale there, and this is where you have got large players in the class that have done very, very well. Fanapt itself actually only represents about 2% of the branded market, and the silver lining to that, obviously, because we want that number to be as big as possible, is that in a class from a branded perspective where there is a handful plus of products, and we have 2%, that means there is significant room for growth, right?

Kevin MoranCFO

As we have seen success in the last two years or so with our commercial expansion, we are optimistic that we could continue to see success both with our continued efforts around bipolar disorder, but also potentially with the label expansion in MDD. In the class itself, there has been some recent entrants with different new mechanisms, which are important to the class for patients and prescribers to have other options. We have also seen the proliferation of LAIs and those becoming a more important part of the class. But Fanapt, we think, has a very important treatment option for patients, for prescribers, and now in the neighborhood of 10,000 people a month are on Fanapt, just to give you some sense of how significant the patient population is. Now, where that kind of dovetails with BYSANTI is that Fanapt's LOE is expected to be towards the end of 2027.

Kevin MoranCFO

We're going to launch BYSANTI before the end of this year, which means that we'll have about a year of overlap where both products are in the market under exclusivity. We've got a very well-built-out commercial infrastructure around our psychiatry sales force and commercial activities that we're going to be pivoting from solely Fanapt to both Fanapt and BYSANTI, and likely over time, to primarily BYSANTI. We feel very well prepared to launch that drug given the existing commercial infrastructure, the existing relationships that we have with prescribers in the broader community. We're very excited to get the product out there and hopefully begin to see success as we head into the end of this year and next year, and then again with the MDD data providing kind of another inflection point for potential growth in the not-too-distant future.

Kevin MoranCFO

One other important dynamic about Fanapt and BYSANTI is from a pricing perspective, BYSANTI has significant favorability relative to Fanapt. On the Fanapt side, as I mentioned, it's been on the market for quite some time, just given kind of how that's evolved over the last 15 years. The gross-to-net on Fanapt is in the neighborhood of 50%, and the primary driver there is the Medicaid business, where the gross-to-net is actually over 100%. You actually lose money, lose revenue on, not even money, just lose revenue, on units sold through the Medicaid channel. With BYSANTI, you get a reset on that calculation of the unit rebate amount, such that we expect the gross-to-net on BYSANTI to be more in the mid-30s, relative to that 50%.

Kevin MoranCFO

The revenue that we're able to derive from BYSANTI units will be significantly higher than the revenue that we're able to derive from Fanapt units, and most specifically in the Medicaid segment, which is about 30%-40% of the Fanapt business, and in a similar range for the broader atypical antipsychotic market.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day